Janthima Methaneethorn
Overview
Explore the profile of Janthima Methaneethorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Leelakanok N, Parmontree P, Petchsomrit A, Methaneethorn J
Int J Clin Pharm
. 2022 Jun;
44(4):873-893.
PMID: 35732860
Background: Levonorgestrel and ulipristal acetate are common emergency oral contraceptives (EOCs). Lack of knowledge and negative attitude toward EOCs pose barriers to the EOCs access and utilization. Aim: This study...
12.
Methaneethorn J
Drug Metab Pers Ther
. 2022 Jun;
PMID: 35708353
Objectives: To determine the impacts of missed phenobarbital (PB) doses on its pharmacokinetics and to investigate the appropriate replacement dosing scheme for various PB missed dose scenarios. Methods: Monte Carlo...
13.
Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R
Asia Pac J Clin Oncol
. 2022 Apr;
19(1):9-26.
PMID: 35415961
Because of the high interindividual pharmacokinetic variability, several population pharmacokinetic (PopPK) models of doxorubicin (DOX) were developed to characterize factors influencing such variability. However, significant predictors for DOX pharmacokinetics identified...
14.
Siritientong T, Thet D, Methaneethorn J, Leelakanok N
Nutrients
. 2022 Mar;
14(3).
PMID: 35276881
Because pharmacokinetic changes in antiretroviral drugs (ARV), due to their concurrent administration with food or nutritional products, have become a clinical challenge, it is necessary to monitor the therapeutic efficacy...
15.
Methaneethorn J, AlEjielat R, Leelakanok N
Drug Metab Pers Ther
. 2022 Feb;
37(3):229-240.
PMID: 35218177
Low dose methotrexate (MTX) is commonly used in the treatment of rheumatoid arthritis. The clinical effect is mediated by its metabolite, methotrexate polyglutamate (MTX-PGn). The drug exhibits high interindividual pharmacokinetic...
16.
Leelakanok N, Petchsomrit A, Methaneethorn J, Pornwattanakavee S
Transl Clin Pharmacol
. 2022 Jan;
29(4):206-215.
PMID: 35024361
World Health Organization (WHO) released the treatment manual of diarrhea in 2005. We aimed to investigate the rationale for selecting medications for acute infective diarrhea in Thai community pharmacies and...
17.
Methaneethorn J, Lohitnavy M, Onlamai K, Leelakanok N
Eur J Drug Metab Pharmacokinet
. 2021 Nov;
47(1):105-116.
PMID: 34817826
Background And Objective: Tacrolimus is a narrow therapeutic index drug with high pharmacokinetic variability, and several tacrolimus population pharmacokinetic (PopPK) models were developed to guide individualized drug dosing. These models,...
18.
Maung N, Methaneethorn J, Wattanavijitkul T, Sriboonruang T
Eur J Hosp Pharm
. 2021 Jul;
29(e1):e57-e62.
PMID: 34285111
Background And Objective: Vancomycin pharmacokinetics have been described by both one- and two-compartment models. One-compartment models are widely used to predict the area under the curve (AUC), a useful parameter...
19.
Methaneethorn J, Leelakanok N
Curr Rev Clin Exp Pharmacol
. 2021 Feb;
17(2):122-134.
PMID: 33622228
Background: The use of levetiracetam (LEV) has been increasing, given its favorable pharmacokinetic profile. Numerous population pharmacokinetic studies for LEV have been conducted. However, there are some discrepancies regarding factors...
20.
Methaneethorn J, Leelakanok N
Eur J Clin Pharmacol
. 2020 Oct;
77(3):291-309.
PMID: 33078242
Aims And Background: Population pharmacokinetics with Bayesian forecasting provides for an effective approach when individualized drug dosing, while phenobarbital is a narrow therapeutic index drug that requires therapeutic drug monitoring....